GUIZHOU SANLI PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.73 CNY | +1.59% |
|
-1.27% | -21.98% |
| Sales 2023 * | 1.56B 215M | Sales 2024 * | 2.09B 289M | Capitalization | 6.04B 834M |
|---|---|---|---|---|---|
| Net income 2023 * | 260M 35.9M | Net income 2024 * | 333M 45.98M | EV / Sales 2023 * | 3.87 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2.89 x |
| P/E ratio 2023 * |
23.2
x | P/E ratio 2024 * |
18.1
x | Employees | 1,557 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 40.36% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.59% | ||
| 1 week | -1.27% | ||
| Current month | -8.11% | ||
| 1 month | -16.69% | ||
| 3 months | -17.29% | ||
| 6 months | -17.80% | ||
| Current year | -21.98% |
1 week
14.04
15.02
1 month
14.0417.47
Current year
11.9220.06
1 year
11.9220.65
3 years
10.7422.82
5 years
8.8244.10
10 years
8.8244.10
| Managers | Title | Age | Since |
|---|---|---|---|
Hai Zhang
CEO | Chief Executive Officer | 39 | 07-12-31 |
Hong Yu Zhang
DFI | Director of Finance/CFO | 61 | 13-08-31 |
Qian Fan Zhang
BRD | Director/Board Member | 39 | 14-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shi Gui Chen
BRD | Director/Board Member | 61 | 22-12-11 |
Qiang Wang
BRD | Director/Board Member | 54 | 22-12-11 |
Hai Zhang
CEO | Chief Executive Officer | 39 | 07-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 14.73 | +1.59% | 5,854,293 |
| 24-04-17 | 14.5 | +2.91% | 5,577,600 |
| 24-04-16 | 14.09 | -3.82% | 6,041,300 |
| 24-04-15 | 14.65 | -2.01% | 6,325,100 |
| 24-04-12 | 14.95 | +0.20% | 3,654,800 |
End-of-day quote Shanghai S.E., April 17, 2024
More quotes
Guizhou Sanli Pharmaceutical Co Ltd is a company mainly engaged in the research and development, production and sales of Chinese patent medicines. The Company's product lines cover various areas, including pediatrics, respiratory systems, cardio-cerebrovascular and gastroenterology. Its main products are Kaihoujian spray (Pediatric Use), Kaihoujian spray and Qiangli Gastrodia Elata Eucommia capsules. The Kaihoujian spray (Pediatric Use) and Kaihoujian spray are used for the treatment of respiratory and oral diseases, and the Qiangli Gastrodia Elata Eucommia capsule is used for the treatment of cardiovascular and cerebrovascular diseases. The Company mainly sells its products through specialized academic marketing.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.73
CNY
Average target price
19.84
CNY
Spread / Average Target
+34.69%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.98% | 821M | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 603439 Stock
